title: Treatment of lentigo maligna with tazarotene 0.1% gel.
abstract: We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Italy. chimenti@uniroma2.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Carrozzo
authors.forename: Luigi
authors.initials: L
authors.lastname: Citarella
authors.forename: Catia
authors.initials: C
authors.lastname: De Felice
authors.forename: Ketty
authors.initials: K
authors.lastname: Peris
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D005782:Gels; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy*; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage*; D012176:Retinoids
chemical_list: D003879:Dermatologic Agents; D005782:Gels; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids